What is the appropriate dosing regimen of Zerbaxa (ceftazidime‑avibactam) for a 76‑year‑old male, weighing 95 kg, height 180 cm, with impaired renal function (serum creatinine 134 µmol/L) after spine fracture surgery, who is currently receiving piperacillin‑tazobactam (Tazocin) empirically?

Zerbaxa Dosing for Renal Impairment

For this 76-year-old male with serum creatinine 134 µmol/L (approximately 1.5 mg/dL), weight 95 kg, and suspected gram-negative infection, calculate creatinine clearance first using the Cockcroft-Gault equation, then dose Zerbaxa (ceftazidime-avibactam) accordingly based on the FDA-approved renal adjustment guidelines.

Step 1: Calculate Creatinine Clearance

Using Cockcroft-Gault equation for males:

• CrCl = [(140 - age) × weight in kg] / (SCr in µmol/L × 0.815)
• CrCl = [(140 - 76) × 95] / (134 × 0.815)
• CrCl = 6080 / 109.21 = approximately 55-60 mL/min

This places the patient in the CrCl 30-50 mL/min range (borderline, but trending toward mild-moderate renal impairment given age and rising creatinine).

Step 2: Determine Infection Type and Appropriate Dose

Given the clinical scenario (post-spine surgery with E. coli in urine and gram-positive cocci in blood), this appears to be a complicated urinary tract infection (cUTI) with possible secondary bacteremia.

FDA-Approved Dosing for cUTI 1:

For CrCl 30-50 mL/min:

• Zerbaxa 750 mg (500 mg ceftazidime + 250 mg avibactam) IV every 8 hours
• Infuse over 1 hour
• Duration: 7 days for cUTI

Critical consideration: If creatinine continues rising or if CrCl drops below 30 mL/min, dose must be reduced to:

• Zerbaxa 375 mg (250 mg + 125 mg) IV every 8 hours for CrCl 15-29 mL/min

Step 3: Practical Administration

The FDA label 1 specifies that for doses requiring fractions (like 750 mg), you must:

1. Reconstitute vials according to package instructions
2. For 750 mg dose: withdraw appropriate volume from reconstituted vial(s) to achieve 500 mg ceftazidime + 250 mg avibactam
3. Add to infusion bag and administer over 1 hour

Important Clinical Caveats

Monitor Renal Function Closely

• Recheck creatinine every 24-48 hours given the rising trend (from normal 120 to 134 µmol/L) 1
• Adjust dose immediately if CrCl drops below 30 mL/min
• Renal impairment led to treatment discontinuation in 0.5% of patients in clinical trials 1

Consider Infection Severity

Recent evidence suggests that renal dose reduction of ceftazidime-avibactam is independently associated with higher mortality in bloodstream infections (HR 4.47, P=0.037) 2. If the patient develops septic shock or severe sepsis, consider:

• Extended infusion (3-4 hours instead of 1 hour) to optimize PK/PD targets 3
• Therapeutic drug monitoring if available 4
• The standard renal-adjusted dose may provide suboptimal exposure in critically ill patients 2

Neurotoxicity Risk

Ceftazidime concentrations >80 mg/L increase neurotoxicity risk 5, but this is unlikely at renal-adjusted doses 6. However, monitor for:

• Confusion
• Seizures
• Encephalopathy

Coverage Gaps

Zerbaxa does NOT cover:

• Gram-positive cocci (your blood culture shows gram-positive cocci pending final ID) 7
• Continue or add appropriate gram-positive coverage (vancomycin if MRSA suspected, or linezolid) until final blood culture identification
• Metallo-β-lactamase producers 7

Hemodialysis Consideration

If patient progresses to ESRD requiring hemodialysis 1:

• Loading dose: 750 mg (500 mg + 250 mg)
• Maintenance: 150 mg (100 mg + 50 mg) every 8 hours
• Administer after dialysis on dialysis days

Summary Dosing Algorithm

1. Current recommendation: Zerbaxa 750 mg IV every 8 hours (based on CrCl ~50-60 mL/min)
2. Recheck creatinine in 24 hours
3. If CrCl drops to 15-29 mL/min → reduce to 375 mg every 8 hours
4. If requires hemodialysis → 750 mg loading, then 150 mg every 8 hours (post-dialysis)
5. Add gram-positive coverage until blood culture finalized
6. Consider extended infusion if patient becomes critically ill